ada glp-1 Generic Liraglutide Approved, Marking First Generic RA Indicated Specifically for Weight Management in the US SURPASS-CVOT plus the 2026 ADA

NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4 mg, and TA664 for liraglutide 3 mg) recommends regular monitoring of patients on GLP-1 therapy, with particular attention to tolerability and adverse effects

By approaching semaglutide and tirzepatide therapy with attention to its medical, psychological, and cultural dimensions, we honor the complex humanity of those seeking better health through these innovative treatments.

This is exactly as it should be

Medicare beneficiaries will now be eligible for obesity treatment coverage if they meet certain conditionssuch as having a BMI over 27 combined with prediabetes or cardiovascular disease